Topic

GLP-1

EMA committee backs Lilly’s obesity pill as the oral GLP-1 race widens

The EMA's human medicines committee recommended approval of Lilly's once-daily orforglipron pill on Oct. 15, as Viking started Phase 3 trials of oral VK2735 and Nature Medicine reported a Phase 3 trial of safiglipron.

October 21, 20264 min read

Nutrition

UK digital program reports 15.5% weight loss at six months in 8,127 women

An observational study in Nature Medicine tracked 8,127 women prescribed GLP-1 drugs, almost all tirzepatide, through a remote UK service. Mean weight loss was 16.1 kg at six months; there was no comparison group.

October 16, 20264 min read